Articles On Amplia Therapeutics (ASX:ATX)

The ASX200 rebounded today and was in the green heading into the close. Investors were buoyant in response to positive inflation data that increased the odds of an interest rate cut in August. Staples, Real Estate and Discretionary were...

Race Oncology (ASX:RAC) has captured the most attention on the HotCopper forums today after successfully – and safely – dosing its first patient with RC220 and RC220 in combination with doxorubicin. Listen to the HotCopper podcast for in...

Telix faces unwanted US regulatory attention – but it’s not alone Amplia raises $25 million, with another $2.5 million to go A home-grown uni biotech innovation shines again   Telix Pharmaceuticals (ASX:TLX) shares this morning slumped up...

ASX slides from record high, down 1.02pc Energy and materials only sectors to lift South32 outperforms production guidance   ASX suffers Liberation Day-sized fall Today was the largest single-day plunge on the ASX since markets went haywi...

ASX biotechs target global cell therapy market, projected to reach ~US$48bn by 2034 Arovella the only ASX-listed biotech delving into CAR iNKT therapies and one of few globally Chimeric aims to ‘break new ground’ in treatment of solid tumo...

It was a tale of two halves for the ASX today, and neither were great  Caution abounds ahead of two major market-moving events this week, including RBA and Trump decisions Utilities stock Origin Energy was a big-cap MVP today, although the...

 Nanosonics has launched tweaked versions of its Trophon medical probe steriliser Amplia shares soar a further 36% on pancreatic cancer promise Dimerix looks to broaden its repertoire     Nanosonics (ASX:NAN) has launched updated iteratio...

ASX hits the breaks, adding just 0.08pc Info tech also contracted, adding 0.54pc compared to more than 1pc earlier in the session Profit taking drives materials, banks lower   3pm slump has ASX yawning to close The ASX 200 pulled back fro...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

Australia’s S&P/ASX 200 rose 1.4% in June, posting gains of almost 10% for Q2 CY25 The S&P/ASX emerging companies was the only index in the red, down 0.41% Codeifai topped June winners, up 600% after announcing it was acquiring mai...

Highlights Bioxyne outpaces sector peers with performance in cannabis and health products Paradigm Biopharmaceuticals secures convertible note funding for late-stage trial Recce Pharmaceuticals and Botanix turn to debt as eq...

Bioxyne stars with a 720% gain in the 2024-25 year Paradigm shares soar 34% after $41 million convertible note deal Biotechs turn to debt funding The ASX biotech sector’s best EOFY performer has come from left field: the local and Europ...

The bourse’s ‘please explain’ to the cancer drug developer has elicited a lengthy response Last week’s tearaway performer, Amplia will launch a second pancreatic cancer trial The private Myro to launch neuroblastoma trial As any wizened s...

This week’s Bulls N’ Bears ASX Runners of the Week is… Amplia Therapeutics. The biotech beauty might just be onto a fabled golden bullet for hard-to-treat pancreatic cancer.

Highlights Australian shares drift as optimism over a rate cut builds after labour report Financials lift but declines in tech, healthcare and materials limit index gains Amplia Therapeutics and uranium miners drive small-ca...

ASX 200 futures are pointing to a -0.2% slide at open today, after it emerged Donald Trump is pondering a direct attack on Iran – a decision he says he’s going to ruminate on for “the next two weeks” before issuing orders. Listen to the...

Markets pricing a 78pc chance of rate cut following labour data Unemployment levels remained steady ASX dips on broad weakness in tech, resources and healthcare stocks   The ASX ended up in negative territory this afternoon, but not by mu...

The ASX 200 traded flat today, as the index keeps tracking sideways for a fourth straight day. Financials, Real Estate, and Discretionary were substantially in the green, while on the other side Materials, Utilities, and IT stocks were s...

Highlights Amplia Therapeutics surges on clinical update in pancreatic cancer trial ASX 200 dampened by declines in tech, energy, and materials sectors Bank stocks and selective healthcare names provide morning stability...

Amplia Therapeutics (ASX:ATX) has been the most watched on HotCopper forums through today after huge results from its ACCENT trials set up to look into how its FAK inhibitor, Narmafotinib, combats cancer. Listen to the HotCopper podcast...

Orthocell says its Remplir nerve device blitzes the stitches Singular Health inks US physician network deal Clarity clearly is undervalued, say brokers   Among other auspicious events, the 19th of June marks the end of slavery in the US,...

Amplia Therapeutics (ASX: ATX) continues to make excellent progress with focal adhesion kinase (FAK) inhibitor narmafotinib, its best-in-class drug candidate for pancreatic cancer. New data from the company’s ongoing ACCENT trial investigat...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am, once trading kicks off in earn...

Highlights Santos (ASX:STO) gains after external proposal confirmed due diligence process Uranium stocks including Boss Energy (ASX:BOE) and Paladin Energy (ASX:PDN) trade higher Energy sector leads early trade on ASX 200...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin HIGHLIGHTS A confirmed pathological complete response has been recorded in the ACCE...

Highlights Energy sector stocks lift the All Ordinaries and ASX 200 in early trade Santos (ASX:STO) receives takeover proposal from overseas consortium Uranium explorers including Deep Yellow (ASX:DYL) and Boss Energy (ASX:B...

Highlights Energy stocks strengthen ASX with significant upward movement Uranium and iron ore companies display broad early momentum Clinical and tech sector updates drive Amplia and archTIS gains  Energy stock...

Highlights Energy sector lifts the ASX 200 in early trading Uranium and oil stocks show strong momentum Activity surges across key players including Santos, Deep Yellow, and Boss Energy The energy segme...

4DS Memory (ASX:4DS) has been the most watched stock on HotCopper forums so far today, on news that its Sixth Platform Lot results did not quite meet expectations. 4DS Memory has been down 58% at 2.6 cents. Listen to the HotCopper podcas...

Amplia Therapeutics (ASX: ATX) has recorded the first pathological complete response (pCR) from a patient participating in the company’s ongoing ACCENT clinical trial to treat metastatic pancreatic cancer. The trial is investigating the com...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am, once trading kicks off in earn...

Highlights  ASX 200 set to rise as confidence surveys and interest rate expectations drive sentiment  Strong sectoral gains led by Financials and Energy boost broader market optimism  Small-cap momentum supported by updates from compa...

Despite a strong start, the ASX has paired back gains to finish down 2.9 points or 0.03pc Weakness came from the Health Care sector and gold stocks Info Tech sector rides semiconductor fever higher, up 0.71pc Despite a strong start to the...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

Highlights ASX 200 futures signal a stronger open amid renewed global optimism US indices rally as tariff tensions ease and consumer sentiment improves Key ASX companies including ASX:GMG, ASX:WEB, ASX:FPH, ASX:IFT and ASX:M...

With some common types of cancers including breast and lung, therapies have developed at a rapid clip. The same can’t be said for pancreatic cancer, which is not among the most common tumours but ranks number one as the deadliest. Only 12%...

US government debt was downgraded from AAA to AA1 Iron ore falls as data out of China shows weakening growth Gold climbs 0.62pc to US$3223/oz   After eight days of gains the ASX has finally stumbled, ending the day down 0.58%. It’s unlike...

Highlights GreenPeak Rare Earths (PEK) rose sharply following acquisition news Brightstar Resources (BTR) advanced with second processing campaign launch Treasury Wine Estates (TWE) declined after leadership change announcem...

Highlights: ASX 200 rebounds after early decline, supported by gains in financials and technology sectors Xero (ASX:XRO) jumps after strong revenue and profit growth despite net profit after tax miss Insurance Australia Grou...

Highlights Amplia Therapeutics (ASX:ATX) surges following positive pancreatic cancer trial update LI-S Energy (ASX:LIS) gains with progress on drone battery platform and lithium foil project ASX 200 opens lower amid broad se...

ASX posts 0.22pc gains, recovering from dip earlier in the day Xero brings big profit and revenue gains in quarterly report, lifting stock 4.7pc Insurance Australia surges 5.7pc on Royal Automobile Club of Western Australia deal   It was...

The ASX200 closed up 0.22% at 8,297 points. IT was the best performing sector, up 2.0%, followed by Financials, up 1.1%, and Discretionary, up 1%. Real Estate was the worst performing sector, down 1.3%, followed by Energy, down 1.1%,...

Amplia Therapeutics (ASX:ATX) has popped over +40% in lunchtime trades as the company reports its products provide superior outcomes when coupled with chemotherapy, at least in one ‘ACCENT’ trial announced on Thursday. “The ACCENT trial...

Amplia says it has reached the requisite level of ‘partial responders’ in its mid-stage pancreatic cancer study Immutep reports “remarkable” response rates in a German-based lung cancer trial Paradigm wins US ethics approval for knee osteo...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10:15, once trading kicks off in earnes...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

By stockpiling components, the US-focused Impedimed is taking no chances with tariffs Cashed-up Amplia forges ahead with promising pancreatic cancer trial Some biotechs are headed to the well, while others are rolling in the green stuff...

AdAlta subsidiary AdCella brings cutting-edge cellular immunotherapies from Asia – particularly China – into Western markets AdCella has backing of SYNthesis BioVentures Fund, which invests in therapeutics development The biotech fund beli...

Highlights Insiders purchased AU$949.9k in ATX stock last year. Current value now stands at AU$714.9k following a 21% decline. Insider ownership is 15% of the company. Over the last year, insiders at Amplia Therapeutics Limited (A...

A cabal of ASX drug developers has defied the US gloom The healthcare jury’s out on new FDA head Dr Marty Makary Emvision’s Emu trial takes flight Amid the downbeat narrative about US healthcare policy and cuts to funding agencies, a ‘Mag...